MX2022013692A - Compuesto que tiene actividad inhibidora de desmetilasa 5 (kdm5) y uso farmaceutico del mismo. - Google Patents

Compuesto que tiene actividad inhibidora de desmetilasa 5 (kdm5) y uso farmaceutico del mismo.

Info

Publication number
MX2022013692A
MX2022013692A MX2022013692A MX2022013692A MX2022013692A MX 2022013692 A MX2022013692 A MX 2022013692A MX 2022013692 A MX2022013692 A MX 2022013692A MX 2022013692 A MX2022013692 A MX 2022013692A MX 2022013692 A MX2022013692 A MX 2022013692A
Authority
MX
Mexico
Prior art keywords
kdm5
azabicyclo
inhibitory activity
hexane derivatives
disease
Prior art date
Application number
MX2022013692A
Other languages
English (en)
Spanish (es)
Inventor
Hidenori Takahashi
Yan Zhang
Akito Kakuuchi
Masaki Asada
Goran Krilov
Shuhei Umemura
Anatoly Ruvinsky
Daigo Inoyama
Kyle Konze
Mats Svensson
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2022013692A publication Critical patent/MX2022013692A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022013692A 2020-05-07 2021-05-06 Compuesto que tiene actividad inhibidora de desmetilasa 5 (kdm5) y uso farmaceutico del mismo. MX2022013692A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020088925 2020-05-07
PCT/CN2021/091843 WO2021223699A1 (en) 2020-05-07 2021-05-06 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof

Publications (1)

Publication Number Publication Date
MX2022013692A true MX2022013692A (es) 2022-11-30

Family

ID=76159223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013692A MX2022013692A (es) 2020-05-07 2021-05-06 Compuesto que tiene actividad inhibidora de desmetilasa 5 (kdm5) y uso farmaceutico del mismo.

Country Status (13)

Country Link
US (3) US11691968B2 (cg-RX-API-DMAC7.html)
EP (2) EP4471027A1 (cg-RX-API-DMAC7.html)
JP (3) JP7643466B2 (cg-RX-API-DMAC7.html)
KR (2) KR102937044B1 (cg-RX-API-DMAC7.html)
CN (1) CN115461338B (cg-RX-API-DMAC7.html)
AU (1) AU2021268223C1 (cg-RX-API-DMAC7.html)
BR (1) BR112022022005A2 (cg-RX-API-DMAC7.html)
CA (1) CA3181604A1 (cg-RX-API-DMAC7.html)
ES (1) ES3037418T3 (cg-RX-API-DMAC7.html)
IL (1) IL297900B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022013692A (cg-RX-API-DMAC7.html)
TW (1) TWI895412B (cg-RX-API-DMAC7.html)
WO (1) WO2021223699A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3999183A4 (en) * 2019-07-17 2023-11-15 Ono Pharmaceutical Co., Ltd. COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES
AU2021268223C1 (en) 2020-05-07 2026-07-09 Ono Pharmaceutical Co., Ltd. Compound having KDM5 inhibitory activity and pharmaceutical use thereof
JP2023070165A (ja) * 2021-11-05 2023-05-18 小野薬品工業株式会社 アザビシクロ環化合物の結晶
JP7743829B2 (ja) * 2021-11-05 2025-09-25 小野薬品工業株式会社 Kdm5阻害作用を有する化合物を含有する医薬組成物
TW202612686A (zh) * 2024-05-17 2026-04-01 日商小野藥品工業股份有限公司 失智症之行動及心理症狀之預防、進展抑制及/或治療劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0311859D0 (en) 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
EP1765379A4 (en) 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
WO2009047161A1 (en) 2007-10-09 2009-04-16 F. Hoffmann-La Roche Ag Chiral cis-imidazolines
EP3204379B1 (en) * 2014-10-10 2019-03-06 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
CN108341819B (zh) 2017-01-22 2021-06-15 南京药捷安康生物科技有限公司 磷酸二酯酶抑制剂及其用途
EP3999183A4 (en) 2019-07-17 2023-11-15 Ono Pharmaceutical Co., Ltd. COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES
AU2021268223C1 (en) 2020-05-07 2026-07-09 Ono Pharmaceutical Co., Ltd. Compound having KDM5 inhibitory activity and pharmaceutical use thereof

Also Published As

Publication number Publication date
BR112022022005A2 (pt) 2022-12-13
CN115461338B (zh) 2024-02-20
US12269817B2 (en) 2025-04-08
JP7643466B2 (ja) 2025-03-11
US20230109293A1 (en) 2023-04-06
US20250214984A1 (en) 2025-07-03
CN115461338A (zh) 2022-12-09
JP7643632B2 (ja) 2025-03-11
KR20260046494A (ko) 2026-04-07
JP2025081677A (ja) 2025-05-27
EP4471027A1 (en) 2024-12-04
JP2024177345A (ja) 2024-12-19
KR20230007352A (ko) 2023-01-12
EP4146645B1 (en) 2025-06-25
IL297900B2 (en) 2026-04-01
US20230271952A1 (en) 2023-08-31
EP4146645A1 (en) 2023-03-15
ES3037418T3 (en) 2025-10-01
KR102937044B1 (ko) 2026-03-09
AU2021268223C1 (en) 2026-07-09
IL297900A (en) 2023-01-01
NZ793960A (en) 2025-12-19
JP2023524547A (ja) 2023-06-12
AU2021268223B2 (en) 2025-10-09
WO2021223699A1 (en) 2021-11-11
CA3181604A1 (en) 2021-11-11
TW202200571A (zh) 2022-01-01
AU2021268223A1 (en) 2022-12-08
US11691968B2 (en) 2023-07-04
IL297900B1 (en) 2025-12-01
TWI895412B (zh) 2025-09-01

Similar Documents

Publication Publication Date Title
SA521422143B1 (ar) 15-pgdh مثبط
WO2020104648A3 (en) TGFβ INHIBITOR AND PRODRUGS
PH12021550045A1 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
NZ539841A (en) Hydroxyethylamine derivatives for the treatment of alzheimer's disease
ZA202204666B (en) 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors
GB0225475D0 (en) Therapeutic agents
ZA202213152B (en) Novel acid secretion inhibitor and use thereof
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
NO20070606L (no) Inhibitorer av IAP
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
GB0318447D0 (en) Therapeutic agents
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
NZ598242A (en) Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
ZA202100352B (en) Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
MX2025010357A (es) Degradador de irak4, y uso del mismo
MX2020004588A (es) Inhibidor de proteasa de doble cabeza.
BR112022022005A2 (pt) Derivado de 3-azabiciclo(3.1.0)hexano tendo atividade inibidora da kdm5 e uso do mesmo
DE60232173D1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
PT1606288E (pt) Derivados de benzenossulfonamida, processo para a sua preparação e a sua utilização para tratamento da dor